Want to see HK:1643 full AI Analyst Report?
Modern Chinese Medicine Group Co. Ltd. (1643) Ratios
Modern Chinese Medicine Group Co. Ltd. Ratios
HK:1643's free cash flow for Q2 2026 was $-57.68M. For the 2026 fiscal year, HK:1643's free cash flow was decreased by $-9.29M and operating cash flow was $-48.39M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 8.54 | 7.20 | 8.93 | 5.49 | 5.24 |
| Quick Ratio | 7.79 | 6.58 | 7.98 | 4.92 | 4.24 |
| Cash Ratio | 5.92 | 4.69 | 5.86 | 3.85 | 3.01 |
| Solvency Ratio | -0.04 | 0.28 | 0.99 | 1.19 | 1.44 |
| Operating Cash Flow Ratio | 0.13 | 1.20 | 0.17 | 1.71 | 0.98 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 285.80M | $ 296.42M | $ 380.87M | $ 323.89M | $ 248.26M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.09 | 1.12 | 1.12 | 1.19 | 1.17 |
| Debt Service Coverage Ratio | -714.59 | 24676.00 | 11048.00 | 6681.00 | 1142.88 |
| Interest Coverage Ratio | -2733.50 | 22329.00 | 13373.40 | 9006.79 | 1393.77 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 49.64 | -7.70 | -3.83 | -2.17 | -1.50 |
| Profitability Margins | |||||
| Gross Profit Margin | 16.07% | 25.78% | 30.28% | 42.73% | 43.92% |
| EBIT Margin | -11.30% | 11.13% | 19.85% | 31.11% | 31.69% |
| EBITDA Margin | -3.27% | 13.93% | 21.73% | 32.54% | 32.44% |
| Operating Profit Margin | -11.30% | 10.43% | 19.43% | 31.55% | 28.59% |
| Pretax Profit Margin | -9.66% | 6.92% | 19.85% | 31.11% | 31.67% |
| Net Profit Margin | -9.34% | 4.52% | 14.18% | 21.98% | 22.67% |
| Continuous Operations Profit Margin | -9.34% | 4.52% | 14.18% | 21.98% | 22.67% |
| Net Income Per EBT | 96.69% | 65.25% | 71.44% | 70.65% | 71.59% |
| EBT Per EBIT | 85.50% | 66.37% | 102.15% | 98.60% | 110.75% |
| Return on Assets (ROA) | -2.43% | 1.79% | 9.23% | 17.51% | 20.65% |
| Return on Equity (ROE) | -2.65% | 2.00% | 10.32% | 20.77% | 24.24% |
| Return on Capital Employed (ROCE) | -3.16% | 4.54% | 13.94% | 29.45% | 30.57% |
| Return on Invested Capital (ROIC) | -3.06% | 2.97% | 9.96% | 20.79% | 21.86% |
| Return on Tangible Assets | -2.43% | 1.79% | 9.24% | 17.52% | 20.67% |
| Earnings Yield | -4.37% | 4.58% | 26.40% | 30.14% | 20.37% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.28 | 2.42 | 3.34 | 5.12 | 5.05 |
| Payables Turnover | 3.91 | 4.88 | 7.67 | 5.83 | 7.02 |
| Inventory Turnover | 4.10 | 5.20 | 5.16 | 5.51 | 3.45 |
| Fixed Asset Turnover | 0.72 | 1.15 | 3.92 | 4.44 | 4.32 |
| Asset Turnover | 0.26 | 0.40 | 0.65 | 0.80 | 0.91 |
| Working Capital Turnover Ratio | 0.47 | 0.62 | 0.96 | 1.38 | 1.99 |
| Cash Conversion Cycle | 155.62 | 146.21 | 132.46 | 74.90 | 126.25 |
| Days of Sales Outstanding | 159.86 | 150.87 | 109.35 | 71.32 | 72.34 |
| Days of Inventory Outstanding | 89.08 | 70.19 | 70.70 | 66.20 | 105.91 |
| Days of Payables Outstanding | 93.32 | 74.84 | 47.59 | 62.61 | 52.01 |
| Operating Cycle | 248.94 | 221.05 | 180.05 | 137.51 | 178.26 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.01 | 0.10 | 0.01 | 0.21 | 0.10 |
| Free Cash Flow Per Share | -0.03 | -0.09 | 0.01 | 0.19 | -0.02 |
| Dividend Paid and CapEx Coverage Ratio | 0.23 | 0.52 | 1.66 | 6.28 | 0.82 |
| Capital Expenditure Coverage Ratio | 0.23 | 0.52 | 1.66 | 10.73 | 0.82 |
| Operating Cash Flow Coverage Ratio | 70.30 | 436.90 | 117.72 | 320.07 | 140.49 |
| Operating Cash Flow to Sales Ratio | 0.03 | 0.28 | 0.02 | 0.31 | 0.16 |
| Free Cash Flow Yield | -5.48% | -26.18% | 1.83% | 39.14% | -3.21% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -22.90 | 21.85 | 3.79 | 3.32 | 4.91 |
| Price-to-Sales (P/S) Ratio | 2.14 | 0.99 | 0.54 | 0.73 | 1.11 |
| Price-to-Book (P/B) Ratio | 0.61 | 0.44 | 0.39 | 0.69 | 1.19 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -18.24 | -3.82 | 54.72 | 2.55 | -31.19 |
| Price-to-Operating Cash Flow Ratio | 62.31 | 3.58 | 21.81 | 2.32 | 6.97 |
| Price-to-Earnings Growth (PEG) Ratio | 0.10 | -0.27 | -0.08 | 0.46 | 0.00 |
| Enterprise Value Multiple | -15.70 | -0.61 | -1.36 | 0.07 | 1.93 |
| Enterprise Value | 72.67M | -18.20M | -101.35M | 9.53M | 225.72M |
| EV to EBITDA | -15.70 | -0.61 | -1.36 | 0.07 | 1.93 |
| EV to Sales | 0.51 | -0.09 | -0.29 | 0.02 | 0.63 |
| EV to Free Cash Flow | -4.38 | 0.33 | -30.00 | 0.08 | -17.54 |
| EV to Operating Cash Flow | 14.97 | -0.31 | -11.96 | 0.08 | 3.92 |
| Tangible Book Value Per Share | 0.75 | 0.81 | 0.79 | 0.70 | 0.57 |
| Shareholders’ Equity Per Share | 0.75 | 0.81 | 0.79 | 0.70 | 0.57 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.03 | 0.35 | 0.29 | 0.29 | 0.28 |
| Revenue Per Share | 0.21 | 0.36 | 0.57 | 0.67 | 0.61 |
| Net Income Per Share | -0.02 | 0.02 | 0.08 | 0.15 | 0.14 |
| Tax Burden | 0.97 | 0.65 | 0.71 | 0.71 | 0.72 |
| Interest Burden | 0.85 | 0.62 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.01 | 0.00 | 0.01 | 0.03 |
| SG&A to Revenue | 0.28 | 0.15 | 0.03 | 0.04 | 0.06 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | -0.37 | 3.98 | 0.17 | 1.01 | 0.50 |
Currency in CNY